Literature DB >> 16128885

Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed.

K van Dijk1, K Fischer, J G van der Bom, D E Grobbee, H M van den Berg.   

Abstract

To quantify variation in clinical phenotype of severe haemophilia we performed a single centre cohort study among 171 severe haemophilia patients. Age at first joint bleed, treatment requirement (i.e. annual clotting factor use), annual bleeding frequency and arthropathy were documented. Because treatment strategies intensified during follow-up, patients were stratified in two age groups: patients born 1968-1985 (n = 91), or 1985-2002 (n = 80). A total of 2166 patient-years of follow-up were available (median 12.0 years per patient). Age at first joint bleed ranged from 0.2 to 5.8 years. Patients who had their first joint bleed later needed less treatment and developed less arthropathy. In patients born 1968-1985 during both on-demand and prophylactic treatment, the 75th percentile of annual joint bleed frequency was consistently four times as high as the 25th percentile. In both age groups variation in annual clotting factor use between 25th and 75th percentiles was 1.4-1.5 times for prophylaxis and 3.8 times for on-demand treatment. To conclude, the onset of joint bleeding is inversely related with treatment requirement and arthropathy and may serve as an indicator of clinical phenotype. Thus, providing a starting point for aetiological research and individualization of treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16128885     DOI: 10.1111/j.1365-2516.2005.01124.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  19 in total

1.  Prophylaxis for adults with haemophilia: one size does not fit all.

Authors:  Kathelijn Fischer
Journal:  Blood Transfus       Date:  2012-04       Impact factor: 3.443

Review 2.  Clinical use of factor VIII and factor IX concentrates.

Authors:  Massimo Morfini; Antonio Coppola; Massimo Franchini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

3.  Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System.

Authors:  R Kulkarni; R J Presley; J M Lusher; A D Shapiro; J C Gill; M Manco-Johnson; M A Koerper; T C Abshire; D DiMichele; W K Hoots; P Mathew; D J Nugent; S Geraghty; B L Evatt; J M Soucie
Journal:  Haemophilia       Date:  2016-11-04       Impact factor: 4.287

4.  Impact of Prothrombotic Risk Factors in a Cohort of Egyptian Hemophilia A Patients.

Authors:  Mona Salah El-Din Hamdy; Aml Soliman Nasr; Manal Mohamed Makhlouf; Zainab Ali El-Saadany; Magy Samir; Dalia Saber Morgan
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

5.  The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B.

Authors:  J Michael Soucie; Paul E Monahan; Roshni Kulkarni; Barbara A Konkle; Marshall A Mazepa
Journal:  Blood Adv       Date:  2018-08-28

6.  Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy.

Authors:  Steffen Rosen; Stefan Tiefenbacher; Mary Robinson; Mei Huang; Jaydeep Srimani; Donnie Mackenzie; Terri Christianson; K John Pasi; Savita Rangarajan; Emily Symington; Adam Giermasz; Glenn F Pierce; Benjamin Kim; Stephen J Zoog; Christian Vettermann
Journal:  Blood       Date:  2020-11-26       Impact factor: 22.113

7.  Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.

Authors:  Kathelijn Fischer; Katarina Steen Carlsson; Pia Petrini; Margareta Holmström; Rolf Ljung; H Marijke van den Berg; Erik Berntorp
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

8.  New treatments in hemophilia: insights for the clinician.

Authors:  Karin Knobe; Erik Berntorp
Journal:  Ther Adv Hematol       Date:  2012-06

Review 9.  Novel therapies and current clinical progress in hemophilia A.

Authors:  Pauline Balkaransingh; Guy Young
Journal:  Ther Adv Hematol       Date:  2017-12-28

10.  Effect of Prophylactic Management of Hemophilia on Bleeding Episodes.

Authors:  Suman Roy; Arun Kumar De
Journal:  Indian J Hematol Blood Transfus       Date:  2018-12-03       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.